Alumis Inc. Common Stock (ALMS) Financial Analysis & Valuation | Quarter Chart
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectio... more
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercializ... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $959.07M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Martin Babler |
| IPO Date | 2024-06-28 | CAGR | — |
| Employees | 237 | Website | www.alumis.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ALMS chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $1.51B | P/E | -1.98 | Forward P/E | -2.7 | PEG | — |
| P/S | — | P/B | — | P/CF | — | P/FCF | — |
| Sales | $7.40M | Sales 1Y | -63.11% | Sales 3Y | — | Sales 5Y | — |
| EPS | $-3.92 | EPS 1Y | -15.93% | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | -4.54% | EPS QoQ | 50% | Sales QoQ Avg | -10.86% | EPS QoQ Avg | -55.14% |
| Gross Margin | 65.76% | Operating Margin | -6204.39% | Profit Margin | -5933.45% | ROCE | -94.76% |
| ROA | -78% | ROE | -103% | Altman Z Score | 0.79 | Piotroski Score | 2 |
| Current Ratio | 6.74 | Quick Ratio | 6.74 | Cash Ratio | 0.84 | Op. CF Ratio | -1.07 |
| Debt/Equity | 0.08 | Debt/Assets | 0.06 | Lt Debt/Equity | 0.07 | Lt Debt/Cap. | 0.07 |
| Intrst Cov. | — | Inventory Turnover | — | Asset Turnover | 0.01 | Receivables Turnover | — |
| Enterprise Value | $1.51B | P/E Ratio | -1.98 |
| Forward P/E | -2.7 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | — |
| P/CF Ratio | — | P/FCF Ratio | — |
| EPS | $-3.92 | EPS Growth 1Y | -15.93% |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -63.11% | Gross Margin | 65.76% |
| Operating Margin | -6204.39% | Profit Margin | -5933.45% |
| ROE | -103% | ROA | -78% |
| ROCE | -94.76% | Current Ratio | 6.74 |
| Quick Ratio | 6.74 | Cash Ratio | 0.84 |
| Debt/Equity | 0.08 | Interest Coverage | — |
| Altman Z Score | 0.79 | Piotroski Score | 2 |
Alumis Inc. Common Stock (ALMS) valuation & financials
Alumis Inc. Common Stock (ALMS) has a market capitalization of $959.07M and trades at a price-to-earnings ratio of -2.0. It operates in the Healthcare sector (Biotechnology).
Alumis Inc. Common Stock's revenue grew -63.1% over the last year.
Alumis Inc. Common Stock's next earnings report is scheduled for November 12, 2026 after market close (provider scheduled date); analysts estimate EPS of $-0.73. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)